About the Authors
- Ales Tichopad
-
* E-mail: he@ceeor.com
Affiliation CEEOR spol. s r.o., Prague, Czech Republic
- Craig Roberts
-
Affiliation Emerging Markets Business Unit, Pfizer Inc., Collegeville, Pennsylvania, United States of America
- Igor Gembula
-
Affiliation CEEOR spol. s r.o., Prague, Czech Republic
- Petr Hajek
-
Affiliation Emerging Markets Business Unit, Pfizer Inc., Collegeville, Pennsylvania, United States of America
- Anna Skoczynska
-
Affiliation Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland
- Waleria Hryniewicz
-
Affiliation Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland
- Karina Jahnz-Rozyk
-
Affiliation Department of Immunology & Allergology, Military Institute of Health Service, Warsaw, Poland
- Roman Prymula
-
Affiliation University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- Ivan Solovič
-
Affiliation I. Department of Pneumology and Ftizeology, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Vysne Hagy, Slovakia
- Vitězslav Kolek
-
Affiliation Department of Pulmonary Diseases and Tuberculosis, University Hospital Olomouc, Olomouc, Czech Republic
Competing Interests
The authors have the following interests. This study was sponsored by Pfizer Inc. CR and PH are employees and shareholders in Pfizer Inc. AT and IG are employed by CEEOR spol. s r.o. AT and IG have received a reimbursement for attending a symposium, a fee for speaking and funds for research; AS received a reimbursement for attending a symposium, a fee for speaking, a fee for organizing education, funds for research, funds for a member of staff and fees for consulting; VH has received a reimbursement for attending a symposium, a fee for speaking and fees for consulting. PR has received a reimbursement for attending a symposium, a fee for speaking, and fees for consulting and funds for research from Pfizer Inc. in the past five years. KJH has served as a principal investigator in clinical trials (A7881013, A6631029) sponsored by Pfizer Inc. in the past five years. VK has no conflict of interest. Pfizer Inc. develops and markets medicines and vaccines for the treatment and prevention of pneumonia. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: AT CR IG PH. Performed the experiments: AT VK IG. Analyzed the data: AT IG. Contributed reagents/materials/analysis tools: AS WH KJR RP IS VK. Wrote the paper: AT CR.